Is Vertex Pharmaceuticals Stock a Buy in 2025? - The Motley Fool

Jan 26, 2025 · VRTX data by YCharts With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now.

CouponFollow Extension

9%
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? - The Motley Fool

3 weeks from now

fool.com

9%
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? - Yahoo Finance

3 weeks from now

Jan 26, 2025 · With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now. …

yahoo.com

72%
OFF

Should You Buy Vertex Pharmaceuticals Stock Hand Over ... - The …

3 weeks from now

Jan 16, 2025 · Vertex Pharmaceuticals (VRTX -0.72%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30?

fool.com

$10
OFF

Vertex Pharmaceuticals' Next Big Chapter? Vertex Stock Surges On ...

3 weeks from now

2 days ago · Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

investors.com

910%
OFF

Is Vertex Pharmaceuticals Stock A Buy In 2025? - Sharewise

3 weeks from now

Jan 26, 2025 · The price for the Vertex Pharmaceuticals Inc. stock decreased slightly today. Compared to yesterday there is a change of -€3.850 (-0.910%). With 59 Buy predictions and 1 …

sharewise.com

$5000
OFF

Got $5,000? 2 Top Healthcare Stocks To Buy In 2025 And Hold …

3 weeks from now

Jan 25, 2025 · The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

fool.com

03%
OFF

Where Will Vertex Pharmaceuticals Be In 10 Years? - The Motley Fool

3 weeks from now

Dec 4, 2023 · Vertex Pharmaceuticals (VRTX -0.03%) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing …

fool.com

FAQs about Is Vertex Pharmaceuticals Stock a Buy in 2025? - The Motley Fool Coupon?

Is vertex stock a good buy right now?

With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now. Image source: Getty Images. Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. ...

Is Vertex Pharmaceuticals a Buy Now that the FDA approved?

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves from sending pain signals to the brain. ...

Is Vertex Pharmaceuticals a no-brainer buy?

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last few weeks, and could have more on the way. ...

Does the Motley Fool recommend Vertex Pharmaceuticals?

The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ...

Should you invest in Vertex Pharmaceuticals?

Vertex Pharmaceuticals' strategy to target areas with high unmet needs should remain successful. Some people make it a New Year's resolution to improve their finances by investing in stocks. It's a laudable goal, and to get started, it's crucial to pick stocks that have the tools to perform well for decades to come. ...

Is Vertex Pharmaceuticals outperforming other biotech companies in 2022?

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is expanding beyond it, with several promising late-stage programs. ...